NCT05692869

A Study of Continuous Blood Pressure Monitoring in Healthy Participants

A Study to Investigate Continuous Blood Pressure Monitoring Using Traditional Device (ABPM) Versus Novel Devices (Biobeat and Aktiia)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 21 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study in healthy participants is to find out whether the traditional ambulatory blood pressure monitor (ABPM) and newer wearable devices (EmbracePlus smartwatch device, Biobeat chest patch device, and Aktiia wrist device) will accurately pick up changes in blood pressure caused by 2 different medications (propranolol and pseudoephedrine). The study will last about 29 days excluding the screening period of 28 days.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Propranolol	Administered orally.
DRUG	Pseudoephedrine	Administered orally.
DEVICE	ABPM and Wearable Novel Devices	ABPM and wearable novel devices including chest patch device, wrist device and smartwatch device worn throughout the trial.
OTHER	No Intervention	No intervention during this period (Control Period)

Timeline

• Start date: 2023-01-31
• Primary completion: 2023-04-04
• Completion: 2023-04-04
• First posted: 2023-01-20
• Last updated: 2023-04-13

Locations

1 site across 1 country: Singapore